L&C Professional Medical Research Institute
Welcome,         Profile    Billing    Logout  
 7 Trials 
28 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Miller, William
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26
TACTiC, NCT04964544: Technology-Assisted Cholesterol Trial in Consumers

Completed
3
1196
US
5 mg rosuvastatin calcium with a Web App (combination product), Crestor 5 mg
AstraZeneca, Concentrics Research LLC, Concentrics Research - STATKING JV, Idea Evolver, The Cleveland Clinic
High Cholesterol
03/23
03/23
HIPPER, NCT02969512: Feasibility of the Hip Instructional Prehabilitation Program for Enhanced Recovery

Completed
N/A
51
Canada
HIPPER, Behavioral: Online prehab education, OASIS Online Educational Webinars, Behavioral: large group education sessions
University of British Columbia, Canadian Institutes of Health Research (CIHR)
Hip Osteoarthritis
04/23
04/23
SNaPR01, NCT03952520: Scaling up an Evidence-based Intervention for Antiretroviral Therapy for PWID in Vietnam: an Implementation Trial

Completed
N/A
1000
RoW
Standard Approach (SA), Tailored Approach (TA)
University of North Carolina, Chapel Hill, National Institute on Drug Abuse (NIDA), Ohio State University, Johns Hopkins University, Hanoi Medical University, Vietnam Administration for HIV/AIDS Control
HIV Infections, Drug Use
07/23
05/24
SMART, NCT04953364: Self-Management for Amputee Rehabilitation Using Technology.

Recruiting
N/A
82
Canada
SMART, Control
University of British Columbia, Canadian Institutes of Health Research (CIHR)
Behavior, Amputation, Lower Limb Amputation Above Knee (Injury), Lower Limb Amputation Below Knee (Injury), Lower Limb Amputation Knee
01/25
02/26
TEAM Wheels, NCT04090177: Training to Enhance Adaptation and Management for Wheelchair Users (TEAMWheels)

Recruiting
N/A
54
Canada
TEAM Wheels
University of Manitoba, Canadian Institutes of Health Research (CIHR), Laval University, University of British Columbia
Mobility Limitation
04/24
06/24
NCT06364813: Co-developing a Novel Intervention to Promote Wellbeing of Family Caregivers of Individuals With Spinal Cord Injury

Not yet recruiting
N/A
40
NA
COMPANION eHealth Program
University of British Columbia, The Craig H. Neilsen Foundation
Spinal Cord Injuries, Caregiver Burden
05/25
11/25
BPrEP, NCT06094634: IGHID 12219 - A Brief Alcohol Intervention for PrEP Users

Recruiting
N/A
564
RoW
The Brief Alcohol Intervention (BAI): Behavioral
University of North Carolina, Chapel Hill, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), Hanoi Medical University, Johns Hopkins University, University of Washington
Unhealthy Alcohol Use
07/27
07/27
Shah, Anil
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Terminated
2
335
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25
Garcia
NCT05303636: LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Recruiting
4
1710
US
LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet
Insud Pharma, Chemo Research
Change in Bone Mineral Density, Bone Loss
07/26
03/27
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Recruiting
3
320
Europe, Canada, US, RoW
sunvozertinib, Pemetrexed+carboplatin
Dizal Pharmaceuticals
Non-small Cell Lung Cancer
02/26
10/27
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
Garcia, Liagnys
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26
Hechavarria, Joaquin H
OSA, NCT06949969: Alesis -1 Obstructive Sleep Apnea Treatment

Recruiting
N/A
70
US
OSA LLLT treatment device, Sham Comparator
Photonica USA, LLC
Obstructive Sleep Apnea
08/25
10/25
Hanabergh, Enrique
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
Kimmel, Bonnie S
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT06373146: A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Active, not recruiting
2
360
US
Tirzepatide, LY3298176, Mibavademab, REGN4461, Tirzepatide-Placebo, Mibavademab-Placebo
Eli Lilly and Company, Regeneron Pharmaceuticals
Obesity
12/25
04/26
NCT06643728: A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Recruiting
2
240
US
Bimagrumab, LY3985863, BYM338, VER201, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
01/27
NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
180
Canada, Japan, US, RoW
Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
01/27
Morrison, Volrick
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
180
Canada, Japan, US, RoW
Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
01/27
NCT06746259: FebriDx® Method Comparison Study Protocol

Recruiting
N/A
800
US
Rapid point of care test to detect host immune response in ARI, Fingerstick test
Lumos Diagnostics, Biomedical Advanced Research and Development Authority
Acute Respiratory Infections (ARIs)
05/25
06/25
Perez, Maylen
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Miller, William
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26
TACTiC, NCT04964544: Technology-Assisted Cholesterol Trial in Consumers

Completed
3
1196
US
5 mg rosuvastatin calcium with a Web App (combination product), Crestor 5 mg
AstraZeneca, Concentrics Research LLC, Concentrics Research - STATKING JV, Idea Evolver, The Cleveland Clinic
High Cholesterol
03/23
03/23
HIPPER, NCT02969512: Feasibility of the Hip Instructional Prehabilitation Program for Enhanced Recovery

Completed
N/A
51
Canada
HIPPER, Behavioral: Online prehab education, OASIS Online Educational Webinars, Behavioral: large group education sessions
University of British Columbia, Canadian Institutes of Health Research (CIHR)
Hip Osteoarthritis
04/23
04/23
SNaPR01, NCT03952520: Scaling up an Evidence-based Intervention for Antiretroviral Therapy for PWID in Vietnam: an Implementation Trial

Completed
N/A
1000
RoW
Standard Approach (SA), Tailored Approach (TA)
University of North Carolina, Chapel Hill, National Institute on Drug Abuse (NIDA), Ohio State University, Johns Hopkins University, Hanoi Medical University, Vietnam Administration for HIV/AIDS Control
HIV Infections, Drug Use
07/23
05/24
SMART, NCT04953364: Self-Management for Amputee Rehabilitation Using Technology.

Recruiting
N/A
82
Canada
SMART, Control
University of British Columbia, Canadian Institutes of Health Research (CIHR)
Behavior, Amputation, Lower Limb Amputation Above Knee (Injury), Lower Limb Amputation Below Knee (Injury), Lower Limb Amputation Knee
01/25
02/26
TEAM Wheels, NCT04090177: Training to Enhance Adaptation and Management for Wheelchair Users (TEAMWheels)

Recruiting
N/A
54
Canada
TEAM Wheels
University of Manitoba, Canadian Institutes of Health Research (CIHR), Laval University, University of British Columbia
Mobility Limitation
04/24
06/24
NCT06364813: Co-developing a Novel Intervention to Promote Wellbeing of Family Caregivers of Individuals With Spinal Cord Injury

Not yet recruiting
N/A
40
NA
COMPANION eHealth Program
University of British Columbia, The Craig H. Neilsen Foundation
Spinal Cord Injuries, Caregiver Burden
05/25
11/25
BPrEP, NCT06094634: IGHID 12219 - A Brief Alcohol Intervention for PrEP Users

Recruiting
N/A
564
RoW
The Brief Alcohol Intervention (BAI): Behavioral
University of North Carolina, Chapel Hill, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), Hanoi Medical University, Johns Hopkins University, University of Washington
Unhealthy Alcohol Use
07/27
07/27
Shah, Anil
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Terminated
2
335
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25
Garcia
NCT05303636: LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Recruiting
4
1710
US
LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet
Insud Pharma, Chemo Research
Change in Bone Mineral Density, Bone Loss
07/26
03/27
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Recruiting
3
320
Europe, Canada, US, RoW
sunvozertinib, Pemetrexed+carboplatin
Dizal Pharmaceuticals
Non-small Cell Lung Cancer
02/26
10/27
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
Garcia, Liagnys
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26
Hechavarria, Joaquin H
OSA, NCT06949969: Alesis -1 Obstructive Sleep Apnea Treatment

Recruiting
N/A
70
US
OSA LLLT treatment device, Sham Comparator
Photonica USA, LLC
Obstructive Sleep Apnea
08/25
10/25
Hanabergh, Enrique
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
Kimmel, Bonnie S
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT06373146: A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Active, not recruiting
2
360
US
Tirzepatide, LY3298176, Mibavademab, REGN4461, Tirzepatide-Placebo, Mibavademab-Placebo
Eli Lilly and Company, Regeneron Pharmaceuticals
Obesity
12/25
04/26
NCT06643728: A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Recruiting
2
240
US
Bimagrumab, LY3985863, BYM338, VER201, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
01/27
NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
180
Canada, Japan, US, RoW
Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
01/27
Morrison, Volrick
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
180
Canada, Japan, US, RoW
Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
01/27
NCT06746259: FebriDx® Method Comparison Study Protocol

Recruiting
N/A
800
US
Rapid point of care test to detect host immune response in ARI, Fingerstick test
Lumos Diagnostics, Biomedical Advanced Research and Development Authority
Acute Respiratory Infections (ARIs)
05/25
06/25
Perez, Maylen
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26

Download Options